Summary

The 3-year extension of the Candesartan Antihypertensive Survival Evaluation in Japan [CASE-J] Study demonstrated comparable efficacy of the angiotensin receptor blocker candesartan and the calcium channel blocker amlodipine on the incidence of cardiovascular events in high-risk hypertensive Japanese patients. As observed in the earlier phase of the study, cadesartan exhibited sustained superiority over amlodipine with regards to reduction in new-onset diabetes throughout the 3-year extended follow up.